U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 4

1.
Fig. 4.

Fig. 4. From: Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery.

Exon 45–55 skipped quasidystrophin ameliorates skeletal muscle pathology in mdx52 mice. (A) H&E staining in quadriceps (Quad), TA, gastrocnemius (GC), and diaphragm (Diaph) muscles of WT (BL6), untreated (no-treat), and treated mdx52 mice (five times i.v. vPMOs). Representative data are shown. (B) Measurement of centrally nucleated fibers (CNFs) after systemic exon 45–55 skipping (treated) and nontreated mdx52 muscles (no-treat) in Quad, TA, and GC muscles. Data (n = 4) are presented as mean ± SD ***P < 0.001.

Yoshitsugu Aoki, et al. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13763-13768.
2.
Fig. 1.

Fig. 1. From: Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery.

Efficacy of exon 45–55 multiskipping in H2K-mdx52 cells in vitro. (A) Structure of full-length and quasidystrophin. The quasidystrophin produced by exon 45–55 deletion (skipping) has a hybrid rod repeat of rods 17 and 22. Actin-bind, actin-binding domain; CRD, cysteine-rich domain; CTD, C-terminal domain. (B) Mdx52 mouse lacks exon 52 in the mRNA of the murine Dmd gene, leading to out-of-frame products (yellow broken line). Exon 45–55 skipping with mixture vPMOs (blue broken line) restores the reading frame of dystrophin mRNA. (C) RT-PCR results after 0.1, 0.3, or 3 μM in total of mixture vPMO transfected into H2K-mdx52 myotubes as indicated. M, molecular marker; 0, no vPMO transfection. (D) Confirmation of correct exon 45–55 block skipping by direct sequencing of the PCR products. Sequencing of the most intense band shows exon 45–55 skipped dystrophin mRNA sequence.

Yoshitsugu Aoki, et al. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13763-13768.
3.
Fig. 3.

Fig. 3. From: Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery.

Systemic i.v. injections of the mixture-ESE2 in mdx52 mice restore dystrophin expression in body-wide skeletal muscles. (A) Immunohistochemical staining of dystrophin exon 57 in quadriceps (Quad), TA, gastrocnemius (GC), triceps brachii (TB), diaphragm (Diaph), and heart muscles in mdx52 mice after five consecutive biweekly systemic injections of 12 mg/kg of the mixture-ESE2. Representative data are shown. BL6TA, TA muscle from wild-type C57/BL6; no-treat TA, untreated TA muscle from mdx52 mice. (Scale bar, 100 μm.) (B) Western blotting analysis with mouse monoclonal antibody DYS2 after the repeated vPMOs systemic injections into mdx52 mice. Representative data are shown. vPMO-injected muscles show 380-kDa quasidystrophin bands (Upper) and α-tubulin (Lower) in Quad, TA, GC, TB, abdominal (Abd), paraspinal (Para), Diaph, and heart muscles of treated mdx52 mice. BL6TA (10% wt/wt), TA muscle from a 10% (wt/wt) extract of wild-type C57/BL6 mice. (C) Semiquantitative analysis of dystrophin expression after AO injection. Data (n = 4) are presented as mean ± SD *P < 0.05; **P < 0.01.

Yoshitsugu Aoki, et al. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13763-13768.
4.
Fig. 2.

Fig. 2. From: Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery.

Exon 45–55 multiskipping and rescue of dystrophin expression in mdx52 mice by local mixture-ESE2 injections. (A) Detection of exon 45–55 skipped dystrophin mRNA by RT-PCR with primers flanking exons 44 (44F1) and 56 (56R1) at 2 wk after injection of mixture-ESE2, targeting exons 45–55 except exon 52 into tibialis anterior (TA) muscles. Representative data are shown. M, molecular marker; no-treat TA, untreated TA muscles from mdx52 mice; treated TA, treated TA muscles from mdx52 mice. (B) Immunohistochemical staining of dystrophin exon 50 in the TA muscle of WT and treated mdx52 mice (Left) and dystrophin exon 57 in the TA muscle of untreated and treated mdx52 mice (Right). Representative data are shown. BL6 TA, TA muscle from a wild-type C57/BL6. (Scale bar, 100 μm.) (C) Percentage of dystrophin-positive fibers after local injections with the 10 vPMO cocktail. Data (n = 6) are presented as mean ± SD ***P < 0.001. (D) Recovery of dystrophin-associated proteins with exon 45–55 skipping. Immunohistochemical staining of dystrophin exons 57, 46, and 50, neuronal nitric oxide synthase (nNOS), α1-syntrophin, and β-dystroglycan in the TA muscle of WT, untreated, and treated mdx52 mice. Representative data are shown. BL6TA, TA muscle from a wild-type C57/BL6; no-treat TA, untreated TA muscles from mdx52 mice. (Scale bar, 100 μm.) (E) Western blotting after the mixture 10 vPMOs local injections to detect the expression of full-length dystrophin, 380-kDa quasidystrophin, nNOS, α1-syntrophin, α-tubulin, β-dystroglycan, and α-sarcoglycan in TA muscles of WT, untreated, and treated mdx52 mice. Representative data are shown.

Yoshitsugu Aoki, et al. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13763-13768.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center